Achieve Life Sciences, Inc.: updates and filings

QUITNASDAQHealthcare · In Vitro & In Vivo Diagnostic Substances

Price

$5.56

November 20, 2026Market cap $612M

What Ploutos Investor adds for Achieve Life Sciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from 2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 24, 2026 latest annualNov 10, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Results of operations
    Form8-K
  • Oct 1, 2026Officer or director change
    Form8-K
  • Aug 17, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 14, 2026Other material events
    Form8-K
  • Aug 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 11, 2026Results of operations
    Form8-K
  • Jul 28, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 8, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 6, 2026Amended articles or bylaws, shareholder vote
    Form8-K
  • Jun 8, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Jun 8, 2026Annual meeting proxy statement
    FormDEF 14A
  • Jun 2, 2026Officer or director change
    Form8-K
  • May 29, 2026Preliminary proxy statement
    FormPRE 14A
  • May 21, 2026Filing
    FormEFFECT
  • May 19, 2026Correspondence with the SEC
    FormCORRESP
  • May 18, 2026Letter from the SEC
    FormUPLOAD
  • May 12, 2026Shares registered for employees
    FormS-8
  • May 12, 2026Shelf registration for future offerings
    FormS-3

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since May 24, 1996: every report, 8-K, meeting and letter. Of its other filings (896 in all), the newest.

The full analysis

What do Achieve Life Sciences's filings show?

The filings are where every one of Achieve Life Sciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.